TRML TOURMALINE BIO INC

Tourmaline Bio to Present at the Leerink Partners Global Healthcare Conference 2025

Tourmaline Bio to Present at the Leerink Partners Global Healthcare Conference 2025

NEW YORK, March 03, 2025 (GLOBE NEWSWIRE) -- Tourmaline Bio, Inc. (Tourmaline) (NASDAQ: TRML), a late-stage clinical biotechnology company developing transformative medicines to dramatically improve the lives of patients with life-altering immune and inflammatory diseases, today announced that Sandeep Kulkarni, MD, Co-Founder and Chief Executive Officer, is expected to participate in the following investor conference:

Leerink's Global Healthcare Conference 2025, Miami

Fireside Chat

Tuesday, March 11, 2025, at 4:20 pm ET

A live webcast and replay, when available, will be available under "Events and Presentations" in the News & Investors section of the Tourmaline Bio website at .

About Tourmaline Bio

Tourmaline is a late-stage clinical biotechnology company driven by its mission to develop transformative medicines that dramatically improve the lives of patients with life-altering immune and inflammatory diseases. Tourmaline’s lead asset is pacibekitug (also referred to as TOUR006). For more information about Tourmaline Bio and pacibekitug, please visit or follow us on or .

Media Contact

Scient PR

Sarah Mishek

  

Investor Contact

Meru Advisors

Lee M. Stern



EN
03/03/2025

Underlying

TRMLTOURMALINE BIO INC

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on TOURMALINE BIO INC

Wedbush Research
  • Wedbush Research
WDC WESTERN DIGITAL CORPORATION
SIMON SILICON MOTION TECHNOLOGY CORPORATION SPONSORED ADR
PSTG PURE STORAGE INC. CLASS A
NVDA NVIDIA CORPORATION
NTAP NETAPP INC.
MU MICRON TECHNOLOGY INC.
INTC INTEL CORPORATION
FATE FATE THERAPEUTICS INC
DKS DICK'S SPORTING GOODS INC.
DIN DINE BRANDS GLOBAL INC.
2330 TAIWAN SEMICONDUCTOR MANUFACTURING CO. LTD.
2303 UNITED MICROELECTRONICS CORP.
SNBR SLEEP NUMBER CORPORATION
MDB MONGODB INC. CLASS A
AMD ADVANCED MICRO DEVICES INC.
AAPL APPLE INC.
MSFT MICROSOFT CORPORATION
IBM INTERNATIONAL BUSINESS MACHINES CORPORATION
ZS ZSCALER INC.
SMCI SUPER MICRO COMPUTER
STX INC.
GFS SEAGATE TECHNOLOGY HLDGS PLC
TRML GLOBALFOUNDRIES INC
TOURMALINE BIO INC
03/06/25 March 6, 2025 1 EN
Dylan Shindler ... (+2)
  • Dylan Shindler
  • Laura Chico
TRML TOURMALINE BIO INC
03/06/25 March 6, 2025 1 EN
 PRESS RELEASE
Free
TRML TOURMALINE BIO ...

Tourmaline Bio to Present at the Leerink Partners Global Healthcare Co...

Tourmaline Bio to Present at the Leerink Partners Global Healthcare Conference 2025 NEW YORK, March 03, 2025 (GLOBE NEWSWIRE) -- Tourmaline Bio, Inc. (Tourmaline) (NASDAQ: TRML), a late-stage clinical biotechnology company developing transformative medicines to dramatically improve the lives of patients with life-altering immune and inflammatory diseases, today announced that Sandeep Kulkarni, MD, Co-Founder and Chief Executive Officer, is expected to participate in the following investor conference: Leerink's Global Healthcare Conference 2025, MiamiFireside ChatTuesday, March 11, 2025, ...

March 3, 2025 1 EN
 PRESS RELEASE
Free
TRML TOURMALINE BIO ...

Tourmaline Bio to Present at the Guggenheim Securities SMID Cap Biotec...

Tourmaline Bio to Present at the Guggenheim Securities SMID Cap Biotech Conference NEW YORK, Jan. 27, 2025 (GLOBE NEWSWIRE) -- Tourmaline Bio, Inc. (Tourmaline) (NASDAQ: TRML), a late-stage clinical biotechnology company developing transformative medicines to dramatically improve the lives of patients with life-altering immune and inflammatory diseases, today announced that Sandeep Kulkarni, MD, Co-Founder and Chief Executive Officer, is expected to participate in the following investor conference: Guggenheim Securities SMID Cap Biotech Conference, New YorkFireside ChatWednesday, Februa...

January 27, 2025 1 EN
 PRESS RELEASE
Free
TRML TOURMALINE BIO ...

Tourmaline Strengthens Cardiovascular Scientific Advisory Board with A...

Tourmaline Strengthens Cardiovascular Scientific Advisory Board with Appointment of Dr. Paul M. Ridker NEW YORK, Jan. 10, 2025 (GLOBE NEWSWIRE) -- Tourmaline Bio, Inc. (Tourmaline) (NASDAQ: TRML), a late-stage clinical biotechnology company developing transformative medicines to dramatically improve the lives of patients with life-altering immune and inflammatory diseases, today announced that Paul M. Ridker, MD, MPH, Eugene Braunwald Professor of Medicine at the Harvard Medical School and Director of the Center for Cardiovascular Disease Prevention at Brigham and Women’s Hospital, has jo...

January 10, 2025 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch